Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2025-05-30 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于不向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of Lingkang Pharmaceutical Group Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('Lingkang Convertible Bonds'). It details the bond issuance, regulatory approvals, previous price adjustments, and the current triggering of the downward adjustment clause, but the board has resolved not to exercise this right at this time. The document is a formal notice about a capital structure matter related to convertible bonds and does not contain financial statements or earnings data. It is not a full financial report, earnings release, or management discussion. It is an update on financing terms and capital structure decisions. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 1744 characters, which is consistent with an announcement rather than a full report.
2025-05-30 Chinese
2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024年年度股东大会决议公告" which translates to "2024 Annual General Meeting Resolution Announcement." It details the date, location, attendance, and voting results of various proposals discussed and approved at the 2024 Annual General Meeting (AGM) of the company. The content includes voting outcomes on the annual board report, supervisory board report, annual report, financial statements, profit distribution plan, credit facility proposals, and amendments to fundraising management rules. The document is a formal announcement of the resolutions passed at the AGM, not the full annual report or financial statements themselves. The document length is 3287 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-23 Chinese
关于“灵康转债”预计满足转股价格修正条件的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding the expected triggering of the convertible bond's conversion price adjustment conditions. It details the bond issuance, the current and historical conversion prices, the conditions under which the conversion price may be adjusted downward, and the company's obligations to disclose such adjustments. The document references regulatory guidelines from the Shanghai Stock Exchange and the China Securities Regulatory Commission. It is a regulatory disclosure about potential changes in convertible bond terms rather than a financial report, earnings release, or management discussion. The document is relatively short (2740 characters) and serves as a formal notice to investors about the possible price adjustment and related procedures. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-05-23 Chinese
上海东方华银律师事务所关于灵康药业集团股份有限公司2024年年度股东大会之法律意见书
Regulatory Filings
2025-05-23 Chinese
2024年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as '2024 年年度股东大会会议资料' which translates to '2024 Annual General Meeting (AGM) Meeting Materials' for Lingkang Pharmaceutical Group Co., Ltd. It contains detailed agenda items for the 2024 Annual General Meeting, including the board of directors' work report, supervisory board report, the full annual report and summary, financial settlement report, profit distribution plan, and other proposals. The document includes meeting procedures, voting instructions, and legal opinions related to the AGM. The content is clearly the materials shared during the AGM rather than the annual report itself or an announcement of the report. The length is substantial (15,000 characters), and it is not a brief announcement or certification. Therefore, the document fits the category of AGM Information (AGM-R).
2025-05-16 Chinese
关于不向下修正“灵康转债”转股价格的公告
Capital/Financing Update Classification · 100% confidence The document is an official announcement from the board of directors of Lingkang Pharmaceutical Group Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds ('Lingkang Convertible Bonds'). It details the bond issuance, regulatory approvals, previous conversion price adjustments, and the triggering of the downward adjustment clause due to stock price performance. The document is a formal notice about a capital/financing matter related to convertible bonds and their conversion price adjustment rights. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is clearly an update on a financing/capital structure issue, specifically about convertible bond terms and board decisions on conversion price adjustments. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 1745 characters, which is consistent with an announcement rather than a full report.
2025-05-09 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.